Hepatitis A infection in patients with chronic viral liver disease: a cross-sectional study in Jahrom, Iran

Abstract

Infection with hepatitis A virus (HAV) in patient with chronic liver disease (CLD; due to hepatitis B or hepatitis C) may cause severe disease and fulminant liver failure. This study aimed to determine the seroprevalence of HAV antibodies in patients infected with HCV or HBV in Iran (Jahrom city). A total of 159 patients with underlying CLD were recruited between September 2012 and February 2013. Serum samples were collected from each patient and tested for anti-HAV using enzyme-linked immunosorbent assay (ELISA). The overall seroprevalence of total anti-HAV was 79·2%. Patients aged 20-30 years had the lowest (28·3%) anti-HAV seropositivity and those aged >50 years had the highest (95%) seropositivity. The overall prevalence of anti-HAV in patients with chronic HCV and HBV infection was 93·7% and 77·1%, respectively. The anti-HAV seropositivity in liver cirrhosis patients was 100% compared to CLD patients. Because of low HAV immunity in younger CLD patients, vaccination against HAV should be considered.

Hepatitis A seroprevalence in patients with chronic viral hepatitis in Konya, Turkey

“…When anti-HAV IgG positivity was assessed in terms of sex, no difference was found in most of the studies as in our study 13 , 14 , 20 , 21 , but there are also study results showing that female sex is an independent risk factor 18 , 19 . More anti-HAV IgG seropositivity was found in female patients in the study carried out in Korea.…”

“…The anti-HAV IgG positivity was found to be statistically higher in our study in patients older than 40 years compared with those younger than 40 years of age. Although an age above 40 years was found to be a risk factor for anti-HAV IgG seropositivity in the Korean study 19 , the anti-HAV IgG seropositivity was found to be significantly higher in chronic hepatitis patients older than 30 years of age in a study carried out in Iran 18 . A study carried out by Saab et al 14 in the USA has shown that patients aged between 51 and 70 years have a higher risk of being exposed to HAV than patients younger than 51 years of age.…”

“…In a study carried out in Iran, the anti-HAV IgG positivity was 79.2% in patients with chronic viral hepatitis, and hepatitis A vaccination was recommended for patients with chronic viral hepatitis who were younger than 30 years old 18 .…”

Seroprevalence of Hepatitis A Virus among Healthy Individuals in Birjand, Eastern Region of Iran

“…Hepatitis A virus (HAV), a member of the Picornaviridae family (1), is an epidemiological important virus with a worldwide distribution and high incidence in low-income countries (2). HAV can be transmitted via different pathways, such as fecal-oral route and contaminated food and water (3).…”

Sero-Epidemiology of Hepatitis E Infections in patients with chronic Hepatitis C virus infection in Jahrom, Southern Iran

“…Decompensation of preexisting cirrhosis as well as increased morbidity and mortality has been reported for HEV1 superinfection among patients with chronic hepatitis C (5). Progression of chronic hepatitis to fulminant hepatitis and cirrhosis due to HCV H Sero-Epidemiology of Hepatitis E in HCV patients infection may be caused by HEV coinfections or other hepatitis agents (6,7). Severe response of the immune system to hepatitis viruses and direct cytopathic effect of HEV can cause liver fibrosis progression and cirrhosis (8).…”